$IDEX Ideanomics CEO Says The Co Is Looking To Enter To The School Bus Sector In Europe

$IDEX Ideanomics CEO Says The Co Is In The Commercial Fleet Operator Space

$IDEX Ideanomics CEO Says Timios Acquisition Is Almost Done; Co Is Waiting For The Regulatory Approval

thoughts?

~ god bless to him (please rest/sleep peacefully)...i miss him so much...

In remembrance of bioman. He taught me to protect my capital,
only go long with free shares. God bless...

Rest in peace biomanbaba.

You will be missed dearly

rest in peace my good friend

PVCT making good moves as minutes expected anyday now

PVCT waiting on minutes from fda

RIP BIOMANBABA WE WILL MISS YOU DEARLY,WE WILL ALWAYS REMEMBER YOU BY THE BIOBOSS OF THE PHARMA INDUSTRY:)

Cellceutix Submits Application to Institutional Review Board to Commence Clinical Trials of Anti-Psoriasis Drug Prurisol

Jan 06, 2014 08:00:00 (ET)

Cellceutix Submits Application to Institutional Review Board to Commence Clinical Trials of Anti-Psoriasis Drug Prurisol

BEVERLY, MA--(Marketwired - Jan 6, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has today submitted the application to the Institutional Review Board ("IRB") responsible for the planned clinical study of the Company's psoriasis drug Prurisol.

The trial is a short crossover study being conducted at the request of the U.S. Food and Drug Administration ("FDA") with the purpose of demonstrating that Prurisol, an ester of abacavir, converts into abacavir in humans, just as it did in animal models. Once IRB approval is received, Cellceutix will immediately file an Investigational New Drug (IND) Application with the FDA. The trial is expected to take approximately one and a half months to complete, at which time the Company will move forward with initiation of a larger Phase 2/3 trial under the guidance from the FDA that a 505(b)(2) designation is an appropriate developmental pathway for Prurisol.

"Submitting the application to the IRB to begin clinical trials of Prurisol is a fantastic way to begin the year," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "We are excited to kick-off 2014 with Prurisol moving into human studies, our novel antibiotic Brilacidin commencing a Phase 2b trial in January, and Kevetrin, our flagship anti-cancer drug, reaching the latter stages of its Phase 1 trial. These trials represent our unwavering commitment to build shareholder value and bring new drugs to market spanning several areas of great unmet medical need."

Cellceutix will be providing a comprehensive update on all of its pipeline developments at the Biotech Showcase 2014 conference being held in San Francisco, California, January 13-15.

About Cellceutix:

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is being readied for clinical trials at sites in the U.S. and Europe. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's key antibiotic, Brilacidin, is set to begin a Phase 2b trial in January 2014 for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy for multi-drug resistant bacteria or a dosing regimen that is shorter than currently marketed antibiotics. Cellceutix has formed research collaborations with world renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends, " "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact:

INVESTOR AND MEDIA CONTACT:

Cellceutix Corp.

Leo Ehrlich

(978) 236-8717

Email Contact

(MORE TO FOLLOW) Dow Jones Newswires

January 06, 2014 08:00 ET (13:00 GMT)

Rest in peace, Henry.

Peace and Respect!

Well said Smooth.
He was a very generous guy and will be missed by many.
RIP Henry.

It is with a heavy heart I pass along the sad news I received today about the passing of the Biomanbaba. I was informed that Henry passed away from a heart attack yesterday at the young age of 62...63 come March. Henry, you will be greatly missed by many of us and especially by the handful of us who knew you as a friend. May you rest in peace my friend until we meet again in heaven.

I was hoping more would have read it and got in but nobody did,ive another that should intrest you and others here

From conversation last week it is clear that IMUC will be removed from this list. Finding a replacement for it on the list will be interesting. Anyone have any ideas to put forth?







In Reply to 'biomanbaba'
My investment thesis is that Cancer will be cured in this decade and the

Magnificent Seven will move us toward the goal CTIX NWBO PCYC THLD SNTA IMUC SBFM

______________________________________________________________

The next Wave will be Regenerative Medicine and a group of biotechs I call the

Cell Biology Seven will lead that wave. ISCO is now the leader of that group and

may become the dominant supplier to others in the field in the same manner that

MSFT came to dominate computer operating systems in prior decades.

The other six are BTX MEDS NNVC BCLI ARWR SRPT

FDA News

Dec 30 (Reuters) - The number of new drugs approved in the United States fell in 2013 compared with the previous year as fewer applications were filed, though several products for hard-to-treat diseases were approved in record time.

The U.S. Food and Drug Administration approved 27 new drugs in 2013, down from a banner year in 2012 which saw 39 drugs approved, the greatest number since 1997 according to FDA data.

The regulatory agency attributed the drop in approvals in 2013 to fewer applications. As of Dec. 11, 32 applications had been filed, compared with 41 for 2012, the FDA said. Over the past five years, the average number of new drug filings per year was 35.

In July 2012, as part of the Food and Drug Administration Safety and Innovation Act, the FDA introduced the "breakthrough therapy" designation to help speed drugs to market that treat serious or life-threatening conditions and where preliminary evidence suggests the drug may work better than existing treatments.

The FDA's Center for Drug Evaluation and Research (CDER) has received 120 requests for breakthrough therapy designation, of which it has granted 36 requests and denied 58. The remainder were pending or withdrawn at the end of the year.

The agency has approved three products so far under the breakthrough therapy program: Roche Holding AG's leukemia drug Gazyva; Johnson & Johnson's drug Imbruvica for mantle cell lymphoma, a rare form of non-Hodgkin lymphoma; and Gilead Sciences Inc's hepatitis C drug Sovaldi.

The number of drugs approved by CDER in 2013, though down from 2012, is close to the historical average over the past five years of 28, according to a recent FDA industry presentation.

The average internal rate of return from pharmaceutical research and development fell to around 4.8 percent in 2013 from 7.2 percent last year and 10.5 percent in 2010, according to a study released earlier this month by Deloitte and Thomson Reuters.

Over the same four-year period, the average cost of developing new medicines rose 18 percent to $1.3 billion, the report found. Yet the average peak sales forecast for each new drug dropped 43 percent to $466 million in 2013 from $816 million in 2010, the report found.

Nonetheless, some analysts remain optimistic that output will increase along with advances in science.

"We are confident that changes to R&D strategies ... will drive a significant improvement in output over the next decade," a Deutsche Bank report said this month.

BIG Brother is on your phone
New York Times
Judge Upholds N.S.A.’s Bulk Collection of Data on Calls
By ADAM LIPTAK and MICHAEL S. SCHMIDT
Published: December 27, 2013


WASHINGTON — A federal judge on Friday ruled that a National Security Agency program that collects enormous troves of phone records is legal, making the latest contribution to an extraordinary debate among courts and a presidential review group about how to balance security and privacy in the era of big data.
Related in Opinion

In just 11 days, the two judges and the presidential panel reached the opposite of consensus on every significant question before them, including the intelligence value of the program, the privacy interests at stake and how the Constitution figures in the analysis.

The latest decision, from Judge William H. Pauley III in New York, could not have been more different from one issued on Dec. 16 by Judge Richard J. Leon in Washington, who ruled that the program was “almost Orwellian” and probably unconstitutional.

The decision on Friday “is the exact opposite of Judge Leon’s in every way, substantively and rhetorically,” said Orin S. Kerr, a law professor at George Washington University. “It’s matter and antimatter.”

The case in New York was brought by the American Civil Liberties Union, which said it would appeal.

“We are extremely disappointed with this decision, which misinterprets the relevant statutes, understates the privacy implications of the government’s surveillance and misapplies a narrow and outdated precedent to read away core constitutional protections,” said Jameel Jaffer, a lawyer with the group.

A spokesman for the Justice Department said, “We are pleased the court found the N.S.A.’s bulk telephony metadata collection program to be lawful.”

The next stops for the parallel cases are the appeals courts in New York and Washington. Should the split endure, the Supreme Court is likely to step in.

In the meantime, the decisions, along with recommendations issued on Dec. 18 by the presidential review group, illustrate the absence of agreement about the effectiveness and legality of the program, which, Judge Pauley said, “vacuums up information about virtually every telephone call to, from or within the United States.” That information is “metadata” — the phone numbers involved, when calls were made and how long they lasted.

The two judges had starkly differing understandings on how valuable that program is.

Judge Pauley, whose courtroom is just blocks from where the World Trade Center towers stood, endorsed arguments made in recent months by senior government officials — including the former F.B.I. director Robert S. Mueller III — that the program might have caught the Sept. 11, 2001, hijackers had it been in place before the attacks.

Judge Pauley began his opinion with an anecdote. In the months before Sept. 11, he said, the N.S.A. intercepted seven calls made to a Qaeda safe house in Yemen from the United States. They were from Khalid al-Mihdhar, who was living in San Diego and would become one of the hijackers.

But the security agency “could not capture al-Mihdhar’s telephone number,” the judge wrote, and “N.S.A. analysts concluded mistakenly that al-Mihdhar was overseas and not in the United States.”

“Telephony metadata would have furnished the missing information and might have permitted the N.S.A. to notify the Federal Bureau of Investigation of the fact that al-Mihdhar was calling the Yemeni safe house from inside the United States,” Judge Pauley wrote.

Judge Leon, in Washington, took the opposite view, saying the government had failed to make the case that the program is needed to protect the nation. “The government does not cite a single instance in which analysis of the N.S.A.’s bulk metadata collection actually stopped an imminent attack, or otherwise aided the government in achieving any objective that was time-sensitive in nature,” he wrote.

The presidential review group took a middle ground, though it seemed to lean toward Judge Leon’s position. It said the security agency “believes that on at least a few occasions” the program “has contributed to its efforts to prevent possible terrorist attacks, either in the United States or somewhere else in the world.” But it added that its own review suggested that the program “was not essential to preventing attacks,” and that less intrusive measures would work.

The group recommended that bulk storage of telephone records by the government be halted in favor of “a system in which such metadata is held instead either by private providers or by a private third party.” Access to the data, it said, should require a court order.

The two judges did not limit their disagreements to how well the program worked. They also drew different conclusions about its constitutionality.

read this! !!


www.senexenergy.com.au/files/720/Demonstrating-the...
Demonstrating the Cooper Basin’s growth potential Ian Davies, Managing Director and Chief Executive Officer James Crowley, General Manager Exploration

^^^ copy/paste that in your browser and look at pages 7,8 it shows the oil ...this is pel 182 but look at the left hand side of the field! those pools go into pel 444 ! it shows it the seismic confirms what ive been telling everybody,this is a great oppty here for cheap shares for TNVMF or holloman

XXII-reaches all time high.

$ECTE PRE-MARKET:
Last: $3.84 Change: +0.91 (+31.06%)

Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA)

Dec 10, 2013 17:42:00 (ET)

Echo to receive a $10 million cash investment from MTIA and Platinum Partners

Company will withdraw the offering identified in recent Form S-1 filing

PHILADELPHIA, Dec. 10, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony(R) CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia (MTIA), Ltd., Hong Kong, for a license arrangement and equity investment in Echo. Under the terms of the License, Development and Commercialization Agreement, dated December 9, 2013, between MTIA and Echo (the "Agreement"), Echo granted MTIA rights to develop, manufacture, market and distribute Echo's Symphony CGM System on an exclusive basis for the Chinese market, including the Peoples' Republic of China, Hong Kong, Macau and Taiwan.

Under the terms of the Agreement, MTIA is responsible for development costs, as well as manufacturing and marketing costs, relating to the Symphony CGM System for the Chinese market, and for obtaining regulatory approval for the product in the licensed territories. Upon the earlier of regulatory approval from the China Food and Drug Administration or upon Echo's termination of the Agreement, MTIA is entitled to reimbursement of development costs up to $1.5 million in the form of shares of Echo's common stock valued at $2.71, which was the NASDAQ closing price on December 9, 2013. The parties will share net sales of the product generated in the territory. The term of the Agreement is ten (10) years, subject to certain rights to earlier termination for breach, change of control and certain performance obligations.

The worldwide market for glucose monitoring devices is approximately $10 billion, and is largely composed of blood glucose meters and test strips which provide single blood glucose values. Symphony has the potential to offer a non-invasive, continuous glucose monitoring solution for use in the emerging hospital market. This strategic partnership offers Echo both the potential to accelerate Symphony's commercialization in China and to access to the Chinese market, where MTIA has established sales channels in more than 1,000 hospitals spanning the country's provinces.

"This collaboration addresses a specific market need in China and we believe that, with our medical device expertise and extensive sales channels, the Symphony CGM System has the potential to revolutionize the standard of care for glucose monitoring in China," said Bai Ge, Managing Director of MTIA. "We are exceptionally pleased to work together with Echo and look forward to a long and productive partnership."

As partial consideration for the Agreement, MTIA and its affiliate purchased 1,818,182 shares of Echo's common stock, par value $0.01 per share, at $2.75 per share, a premium to NASDAQ's closing market price of Echo's common stock on December 9, 2013. MTIA will also receive 181,818 warrants, having a five-year term and an exercise price of $2.75 per warrant. The warrants are exercisable commencing on June 9, 2014. Additionally, Platinum Partners and certain of its affiliates, increased their position in Echo by purchasing 69,569 shares of Echo's common stock at $2.75 per share, a premium to NASDAQ's closing market price on December 9, 2013. Platinum is also purchasing 1,748,613 shares of Series E Convertible Preferred Shares at a purchase price of $2.75 per share which are convertible into shares of Echo's common stock on a one-for-one basis. Platinum will also receive 181,818 warrants on the same terms and conditions as the warrants issued to MTIA. The securities are subject to certain piggy-back registration rights. As a result of the investment in the Company of $10 million, Echo will withdraw the registration statement on Form S-1 filed by the Company on December 2, 2013. The Company had filed the Form S-1 as a potential back-up financial alternative in the event that negotiations with MTIA were not successful.

"We are excited to be working with MTIA in this new relationship to meet the growing glucose monitoring needs in China. We believe MTIA's expertise and relationships in China will enhance Echo's success in this region and our overall value proposition," said Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, Inc. "In addition to strengthening the balance sheet, this $10 million cash infusion, following the recent positive clinical results for use of our Symphony CGM System, represents an important achievement for Echo as we progress toward regulatory clearance."

"Platinum's decision to invest in Echo at this time reflects our view of the Company's opportunity for future growth and confidence in the technology and we congratulate the new management and the Board of Directors for working diligently to close this deal which we are confident will create shareholder value and help deliver against the Company's strategic goals. As a result of the MTIA collaboration, we believe that Echo can leverage MTIA's manufacturing and clinical development skills and capitalize on the significant Chinese market," said Michael M. Goldberg M.D., Principal of Platinum-Montaur Life Sciences, LLC. "This investment reinforces Platinum's long-term commitment to Echo."

"The Company is pleased to finally have the opportunity to arrange this constructive financing with Platinum and to partner with MTIA, who was introduced to us by Platinum, after extensive due diligence and product development analyses. Although this joint process took more time than all three parties initially anticipated, its comprehensive and cooperative nature has been highly beneficial to the alignment of our interests and that of all of our shareholders," added Robert Doman.

About Medical Technologies Innovation Asia

Medical Technologies Innovation Asia (MTIA) is a fully integrated medical device company focused on accelerating and delivering game-changing technologies that improve existing standards of care to meet unmet significant clinical needs and challenges, especially in oncology, diabetic, cardiovascular and other aging-related disease. Headquartered in Hong Kong, the company has manufacturing and sales facilities throughout mainland China. MTIA has established sales channels in more than 1,000 hospitals across China's provinces, including national, top-tier regional and military institutions. MTIA is also the leading investor to pilot a number of State-Owned Enterprise giants of China in the healthcare area plus one of the potentially biggest market capitalization pharmaceutical companies who also has dramatic marketing and sales presence in the diabetic and cardiovascular disease treatment field.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude(R) SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including Symphony's market potential and its commercialization in China, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Christine H. Olimpio

Director, Investor Relations and Corporate Communications

(215) 717-4104

colimpio@echotx.com

Connect With Us:

- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.

/Web site: http://www.echotx.com


(END) Dow Jones Newswires

December 10, 2013 17:42 ET (22:42 GMT)

Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA)

Echo to receive a $10 million cash investment from MTIA and Platinum PartnersCompany will withdraw the offering identified in recent Form S-1 filingPHILADELPHIA,?Dec. 10, 2013?/PRNewswire/ --?Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony??CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia (MTIA), Ltd.,?Hong Kong, for a license arrangement and equity investment in Echo. Under the terms of the License, Development and Commercialization Agreement, dated?December 9, 2013, between MTIA and Echo (the "Agreement"), Echo granted MTIA rights to develop, manufacture, market and distribute Echo's Symphony CGM System on an exclusive basis for the Chinese market, including?the Peoples' Republic of China,?Hong Kong,?Macau?and?Taiwan.Under the terms of the Agreement, MTIA is responsible for development costs, as well as manufacturing and marketing costs, relating to the Symphony CGM System for the Chinese market, and for obtaining regulatory approval for the product in the licensed territories.? Upon the earlier of regulatory approval from the China Food and Drug Administration or upon Echo's termination of the Agreement, MTIA is entitled to reimbursement of development costs up to?$1.5 million?in the form of shares of Echo's common stock valued at?$2.71, which was the NASDAQ closing price on?December 9, 2013.? The parties will share net sales of the product generated in the territory.? The term of the Agreement is ten (10) years, subject to certain rights to earlier termination for breach, change of control and certain performance obligations.The worldwide market for glucose monitoring devices is approximately?$10 billion, and is largely composed of blood glucose meters and test strips which provide single blood glucose values. Symphony has the potential to offer a non-invasive, continuous glucose monitoring solution for use in the emerging hospital market. This strategic partnership offers Echo both the potential to accelerate Symphony's commercialization in?China?and to access to the Chinese market, where MTIA has established sales channels in more than 1,000 hospitals spanning the country's provinces."This collaboration addresses a specific market need in?China?and we believe that, with our medical device expertise and extensive sales channels, the Symphony CGM System has the potential to revolutionize the standard of care for glucose monitoring inChina," said Bai Ge, Managing Director of MTIA. "We are exceptionally pleased to work together with Echo and look forward to a long and productive partnership."As partial consideration for the Agreement, MTIA and its affiliate purchased 1,818,182 shares of Echo's common stock, par value$0.01?per share, at?$2.75?per share, a premium to NASDAQ's closing market price of Echo's common stock on?December 9, 2013. MTIA will also receive 181,818 warrants, having a five-year term and an exercise price of?$2.75?per warrant.? The warrants are exercisable commencing on?June 9, 2014.? Additionally, Platinum Partners and certain of its affiliates, increased their position in Echo by purchasing 69,569 shares of Echo's common stock at?$2.75?per share, a premium to NASDAQ's closing market price onDecember 9, 2013. Platinum is also purchasing 1,748,613 shares of Series E Convertible Preferred Shares at a purchase price of$2.75?per share which are convertible into shares of Echo's common stock on a one-for-one basis.? Platinum will also receive 181,818 warrants on the same terms and conditions as the warrants issued to MTIA.? The securities are subject to certain piggy-back registration rights.? As a result of the investment in the Company of?$10 million, Echo will withdraw the registration statement on Form S-1 filed by the Company on?December 2, 2013. The Company had filed the Form S-1 as a potential back-up financial alternative in the event that negotiations with MTIA were not successful."We are excited to be working with MTIA in this new relationship to meet the growing glucose monitoring needs in?China. We believe MTIA's expertise and relationships in?China?will enhance Echo's success in this region and our overall value proposition," said?Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, Inc. "In addition to strengthening the balance sheet, this?$10 million?cash infusion, following the recent positive clinical results for use of our Symphony CGM System, represents an important achievement for Echo as we progress toward regulatory clearance.""Platinum's decision to invest in Echo at this time reflects our view of the Company's opportunity for future growth and confidence in the technology and we congratulate the new management and the Board of Directors for working diligently to close this deal which we are confident will create shareholder value and help deliver against the Company's strategic goals. As a result of the MTIA collaboration, we believe that Echo can leverage MTIA's manufacturing and clinical development skills and capitalize on the significant Chinese market," said?Michael M. Goldberg M.D., Principal of Platinum-Montaur Life Sciences, LLC. "This investment reinforces Platinum's long-term commitment to Echo.""The Company is pleased to finally have the opportunity to arrange this constructive financing with Platinum and to partner with MTIA, who was introduced to us by Platinum, after extensive due diligence and product development analyses. Although this joint process took more time than all three parties initially anticipated, its comprehensive and cooperative nature has been highly beneficial to the alignment of our interests and that of all of our shareholders," added?Robert Doman.About Medical Technologies Innovation AsiaMedical Technologies Innovation Asia (MTIA) is a fully integrated medical device company focused on accelerating and delivering game-changing technologies that improve existing standards of care to meet unmet significant clinical needs and challenges, especially in oncology, diabetic, cardiovascular and other aging-related disease. Headquartered in?Hong Kong, the company has manufacturing and sales facilities throughout mainland?China. MTIA has established sales channels in more than 1,000 hospitals across?China's?provinces, including national, top-tier regional and military institutions. MTIA is also the leading investor to pilot a number of State-Owned Enterprise giants of?China?in the healthcare area plus one of the potentially biggest market capitalization pharmaceutical companies who also has dramatic marketing and sales presence in the diabetic and cardiovascular disease treatment field.?About Echo TherapeuticsEcho Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting.?Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting.?Echo is also developing its needle-free skin preparation component of Symphony, the Prelude??SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts, including Symphony's market potential and its commercialization in?China, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended?December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Christine H. OlimpioDirector, Investor Relations and Corporate Communications?(215) 717-4104??colimpio@echotx.com

Status update....My commentary may be minimal during the balance of 2013. Interests outside of IHUB are taking up substantial amounts of my time.The lack of remarks should NOT be considered any change of opinion by me.

This one referred to in yours has more science based DD
http://www.pvct.com/news/OncologyNews-Nov-2013.pdf

http://www.moffitt.org/home/moffitt-in-the-news/press-releases/2013/pilon-thomas-rose-bengal

this one:http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94726934

that stock and pizer filed a patent together
WIPO logo Mobile | Deutsch | Español | Français | ??? | ??? | Português | ??????? | ?? |
PATENTSCOPE

--------------------------------------------------------------------------------

Search International and National Patent Collections

World Intellectual Property Organization

closeOptions
Query

Result

Interface

Office

Translate




Query Language All English German Korean Spanish
Arabic Estonian Hebrew Portuguese Vietnamese
Chinese French Japanese Russian

Stem
Sort by: Relevance Pub Date Desc Pub Date Asc App Date Desc App Date Asc

List Length 10 50 100 200


Result List Language Query Language Vietnamese French Russian Arabic
English Hebrew German Korean Estonian
Spanish Portuguese Japanese Chinese

Displayed Fields Application Number Abstract Int. Class Inventor Name
Publication Date Applicant Name Image

Chart/Graph Table Graph

Group by None All IPC code All applicants All inventors Filing Dates Countries
Offices Main IPC Main applicant Main inventor Publication Dates

No of Items/Group 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
More Like This

Default Search Form Simple Advanced Search Field Combination Browse by Week (PCT) Cross Lingual Expansion Translator
Default Tab Search Form Front Page Any Field Full Text ID/Numbers IPC Names Dates
Interface Language English Deutsch Français Español ??? ?? ??? Português ???????
Skins Default Plain Blue_Sky Classic Deep_Marine Emerald_Town Japan_Cherry Ruby Wine
Multiple Windows Interface
Tooltip Help
IPC Tooltip Help

Office: All
All
PCT
Africa
ARIPO Kenya Morocco South Africa

Americas
United States of America
LATIPAT
Argentina Brazil Chile Colombia Costa Rica Cuba Dominican Rep.
Ecuador El Salvador Guatemala Honduras Mexico Nicaragua Panama
Peru Uruguay

Asia-Europe
Bahrain China European Patent Office Israel Japan
Jordan Russian Federation Russian Federation (USSR data) Singapore Spain
Republic of Korea Viet Nam United Arab Emirates


Display the Google widget for translating results
Google Translate of description and claims
Microsoft translate of description and claims




Search
Simple
Advanced Search
Field Combination
Cross Lingual Expansion
Browse
Browse by Week (PCT)
Sequence listing
IPC Green Inventory
Portal to patent registers
Translate
Translation Assistant for Patent Titles and Abstracts
Options
Sort Graph Show Options
News
PATENTSCOPE News
Login
Login
Account Sign Up
Help
How to Search Data Coverage FAQ
Feedback&Contact
INID codes
Kind codes
About User Guide PATENTSCOPE
User Guide: Cross Lingual Expansion
Query Syntax
Fields Definition
Country Code
PCT applications
PCT national phase entry
National collections
Overview
Terms And Conditions
Disclaimer


Home IP Services PATENTSCOPE 1. (WO2012122444) COMBINATION OF LOCAL AND SYSTEMIC IMMUNOMODULATIVE THERAPIES FOR ENHANCED TREATMENT OF CANCER

PCT Biblio. Data

Description

Claims

National Phase

Notices

Drawings

Documents



Latest bibliographic data on file with the International Bureau PermaLinkbookmark icon
PermaLink Bookmark

--------------------------------------------------------------------------------


Pub. No.: WO/2012/122444 International Application No.: PCT/US2012/028412
Publication Date: 13.09.2012 International Filing Date: 09.03.2012

IPC: C12P 21/08 (2006.01)
C CHEMISTRY; METALLURGY
12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21 Preparation of peptides or proteins
08 Monoclonal antibodies


Applicants: PROVECTUS PHARMACEUTICALS, INC. [US/US]; 7327 Oak Ridge Highway Knoxville, TN 37931 (US) (For All Designated States Except US).
PFIZER, INC. [US/US]; 235 East 42nd Street New York, New York 10017 (US) (For All Designated States Except US)
Inventors: EAGLE, Craig J.; (US).
DEES, H. Craig; (US).
WACHTER, Eric A.; (US).
SINGER, Jamie; (US)
Agent: MURPHY, Mark J.; Husch Blackwell LLP 120 South Riverside Plaza, Suite 2200 Chicago, IL 60606 (US)
Priority Data: 61/451,395 10.03.2011 US

Title (EN) COMBINATION OF LOCAL AND SYSTEMIC IMMUNOMODULATIVE THERAPIES FOR ENHANCED TREATMENT OF CANCER
(FR) COMBINAISON DE THÉRAPIES IMMUNOMODULATRICES LOCALES ET SYSTÉMIQUES POUR L'AMÉLIORATION DU TRAITEMENT DU CANCER

Abstract: front page image
(EN)A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
(FR)La présente invention concerne une méthode de traitement du cancer comprenant l'administration d'une quantité thérapeutiquement active d'une composition pharmaceutique chimio-ablative intra-lésion, ou d'une variante d'une telle composition, en combinaison avec une quantité thérapeutiquement active d'un agent anticancéreux immunomodulateur systémique. La présente invention concerne en outre une méthode de traitement du cancer comprenant l'administration d'une quantité thérapeutiquement active d'une composition pharmaceutique chimio-ablative intra-lésion, ou d'une variante d'une telle composition, en combinaison avec une quantité thérapeutiquement active d'un agent anticancéreux ciblé systémique. La présente invention concerne également des compositions pharmaceutiques de traitement du cancer. La composition pharmaceutique chimio-ablative intra-lésion peut inclure un agent chimio-ablatif intra-lésion comprenant principalement un xanthène halogéné.

Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)

seems the longs sold into the surge.

here is a good article concerning that stock!
http://provectuspharmaceuticalsinc.blogspot.com/

I believe dec 16th they will have a name change and be incorporated in delaware and are meeting with fda this month too

somebody that loves and is pro starbucks told me about it... ;)

ok,i got cur today at the open hoping for a December catalyst,that other looks very interesting indeed

It should be studied. Bring whatever you find to the board.

that one is a long term play. I think their product will be successful but the share price price may not reflect it until after Kevetrin comes in or CUR moves etc. I dont have room for it in my current strategy

An excellent article Bucky thanks for bringing it to the board. All should read.

how about this one?
http://seekingalpha.com/article/1732082-provectus-pharmaceuticals-up-17-in-a-month-potential-still-huge?source=yahoo

I dont know the answer to that one. It is usually reported

http://seekingalpha.com/article/1732082-provectus-pharmaceuticals-up-17-in-a-month-potential-still-huge?source=yahoo

cur...I got this,what does it mean?

learning curve Member Level Thursday, 12/05/13 09:08:04 PM
Re: None



Post # of 1632






How come there is no price associated with the Form 4 today?

should this be considered as a bio pick,it looks good
http://seekingalpha.com/article/1732082-provectus-pharmaceuticals-up-17-in-a-month-potential-still-huge?source=yahoo

any thoughts?
http://ih.advfn.com/p.php?pid=nmona&article=60245509

22nd Century Group, Inc. CEO to Webcast, Live, at RetailInvestorConferences.com on December 5th
Company invites Main Street, analysts and Wall Street investors to attend interactive real-time virtual conference

NEW YORK, Dec. 2, 2013 /PRNewswire/ -- 22nd Century Group, Inc. (OTCBB: XXII) today announced that Joseph Pandolfino, Chief Executive Officer, and Henry Sicignano III, President, will present at RetailInvestorConferences.com.

DATE:
December 5, 2013

TIME:
1:15 PM EST

LINK:
www.retailinvestorconferences.com click on the red "register / watch event now" button


This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

The Retail Investor Conferences event is part of the Virtual Investor Conference Series co-hosted by MUNCmedia, Better Investing (NAIC) and PR Newswire. Individual investors, institutional investors, financial advisors and financial analysts are invited to attend.

It is recommended that investors pre-register to save time and receive event updates.

If you log on to their website you can still hear the conference call that followed that announcement

outstanding results as you forecasted

Rock and Roll Starbux

Those who ignored your call are now eating CROW huh?
We told them to buy now or pay up later

It is now time for the procrastinators to PAY UP

star! awesome congrats!